SIFI Receives COMP Positive Opinion on Orphan Drug Designation for Polihexanide in Treating Fungal Keratitis

Contributed by: PR Newswire

Tags

SIFI-S.p.A.

More Like This

SIFI receives positive CHMP opinion for AKANTIOR® (polihexanide 0.08%) in acanthamoeba keratitis

SIFI announces allowance of patent on polihexanide for Europe and commercial launch of AKANTIOR® in Germany

SIFI Receives European Commission Approval for AKANTIOR®

Adam Plich, Founder & CEO, Avanzanite Bioscience B.V. (Photo: Business Wire)

Avanzanite Bioscience Reports AKANTIOR® Received Positive CHMP Opinion and Announces Corporate Expansion Into 26 European Countries

Avanzanite Bioscience Reports European Commission's Authorisation of Orphan Medicinal Product AKANTIOR®

Business Wire logo

Mundipharma and Cidara Therapeutics receive positive CHMP opinion for rezafungin for the treatment of Invasive Candidiasis in adults1

Kyowa Kirin and Swixx BioPharma announce expansion of access to POTELIGEO® (mogamulizumab) for adults living with mycosis fungoides or Sézary syndrome in Central and Eastern Europe

European Medicines Agency Committee for Orphan Medicinal Products provides positive opinion on Calliditas' application for setanaxib in Alport syndrome